Regional Analysis
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
Sprycel Market Regional Insights
- North America is the second largest market for Sprycel, with a CAGR of 2.7% during the forecast period. This is due to the high prevalence of chronic myeloid leukemia (CML) in the region. According to the American Cancer Society, an estimated 14,620 people will be diagnosed with CML in the U.S. in 2023. It holds 30% market share.
- Europe is expected to be the third-largest market for Sprycel, with a CAGR of 2.3% during the forecast period. This is due to the increasing prevalence of CML in the region. According to the European Society for Medical Oncology, an estimated 30,000 people will be diagnosed with CML in Europe in 2023. It holds 18% market share.
- Asia Pacific is expected to be the largest market for Sprycel, with a CAGR of 3.0% during the forecast period. This is due to the rising incidence of CML in the region. According to the World Health Organization, an estimated 250,000 people will be diagnosed with CML in Asia Pacific in 2023. It holds 45% market share.
U.S.: 
U.K. : 
India : 
